An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) has appointed Dr. Sandra M. Swain to its Board of Directors. Dr. Swain brings over 30 years of expertise in breast cancer research and currently serves as Associate Dean at Georgetown University Medical Center. Her involvement aligns with Seagen's mission to advance cancer treatments. The company is noted for its successful portfolio with four approved drugs and a focus on antibody-drug conjugates, reflecting its commitment to improving patient care globally.
Positive
Dr. Swain's extensive experience enhances the Board's expertise, particularly in HER2-positive metastatic breast cancer.
The appointment aligns with Seagen's mission to advance targeted cancer therapies, indicating a strong focus on unmet medical needs.
Negative
None.
BOTHELL, Wash.--(BUSINESS WIRE)--
Seagen Inc. (Nasdaq: SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company’s Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee.
“We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positive metastatic breast cancer,” said Felix J. Baker, Ph.D., Chair of the Seagen Board of Directors. “Her success in advancing treatments to address unmet medical needs of patients aligns directly with Seagen’s mission and our efforts to bring important, targeted medicines to cancer patients worldwide.”
“As a medical oncologist who has cared for many patients with breast cancer, it is an honor to join the board of a company advancing important medicines that can meaningfully improve patient care,” said Dr. Swain. “Seagen is on a great trajectory with four approved medicines, a differentiated and diverse pipeline, leadership in antibody-drug conjugates and a talented team dedicated to patients in need. I look forward to contributing to the Board to support Seagen’s vision of improving the lives of people with cancer.”
Prior to her current roles at Georgetown University and MedStar Health, Dr. Swain held roles at the National Cancer Institute, National Institutes of Health, the Washington Cancer Institute at MedStar Washington Hospital Center, and FDA Oncologic Drugs Advisory Committee. She is a fellow of the American College of Physicians and ASCO. Dr. Swain has served on ASCO’s board of directors and is a past president (2012-2013). She has published over 335 articles, including many regarding clinical trials in breast cancer. Dr. Swain holds an M.D. from the University of Florida and a B.A. in Chemistry from the University of North Carolina.
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the trajectory of the company, its pipeline, and its efforts to bring important, targeted medicines to cancer patients worldwide. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials, the possibility of adverse regulatory actions and the risk that the company’s trajectory may not be as expected. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Who is Dr. Sandra M. Swain and what is her role at Seagen?
Dr. Sandra M. Swain has been appointed to Seagen's Board of Directors, bringing over 30 years of breast cancer clinical research experience.
What is the significance of Dr. Swain's appointment to Seagen?
Her expertise in breast cancer may strengthen Seagen's efforts in developing targeted therapies, especially for HER2-positive metastatic breast cancer.
What is Seagen's current focus in cancer treatment?
Seagen is focused on advancing targeted medicines, with a strong pipeline including four approved drugs and a leadership role in antibody-drug conjugates.
How might Dr. Swain's appointment impact Seagen's future?
Her leadership may contribute to Seagen's strategic direction and enhance its research capabilities, potentially leading to improved patient outcomes.
